Hercules Pharmaceuticals
Leiden
About Hercules Pharmaceuticals
Hercules is a biopharmaceutical company developing an innovative, oral, non-toxic drug therapy for chronic treatment of patients with Triple Negative Breast Cancer, and other solid tumors. The company has demonstrated that blocking the Aryl hydrocarbon Receptor in solid tumors could: Enhance the response of the immune system to cancer Reduce the chance of future relapses by reducing the number of Cancer Stem Cells Reduce metastatic behavior Reduce agression of existing cancer Make cancer cells more sensitive to standard chemotherapy Hercules have discovered novel anti-cancer drugs that block the Aryl Hydrocarbon receptor and is now testing these products in preparation for clinical trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $50K – $100K
- Total funding: $353.9K
- Funding stage: Seed
- Last round: Seed (Aug 2017)
- Website: hercules-pharma.nl
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Clinical Trials
Canonical: https://fsome.com/organization/hercules-pharmaceuticals-73082 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.